ALD 102
Alternative Names: ALD-102Latest Information Update: 09 Apr 2025
At a glance
- Originator Aldena Therapeutics
- Class Anti-inflammatories; Skin disorder therapies; Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Alopecia areata
- Preclinical Skin disorders
Most Recent Events
- 24 Mar 2025 Phase-I/II clinical trials in Alopecia areata in Canada (Intradermal) (NCT06826196)
- 24 Mar 2025 Phase-I/II clinical trials in Alopecia areata in USA (Intradermal) (NCT06826196)
- 13 Feb 2025 Aldena Therapeutics plans to initiate a phase Ib/IIa trial for Alopecia Areata (Intradermal) (NCT06826196)